Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Omvoh Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy ID_CHS_6239

    Mirikizumab-mrkz (Omvoh) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_6239 alerts

    Get alerted when Policy ID_CHS_6239 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of mirikizumab-mrkz (Omvoh) for adults with moderately to severely active ulcerative colitis or Crohn's disease, including prescriber, documentation, clinical response, safety, and continuation requirements.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMirikizumab-mrkz (Omvoh) Coverage Criteria
    Policy CodePolicy ID_CHS_6239
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for coverage, and the medication must be prescribed by or in consultation with a gastroenterologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved covered adult indications
    12 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    GastroenterologistRequired specialty

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    No concomitant biologic or targeted synthetic drug
    Same-indication therapy restriction
    TennesseeState mandate jurisdiction

    Coverage Criteria

    Initial Therapy — Ulcerative Colitis

    Coverage may be authorized for 12 months when ALL of the following are met:

    ALL of the following

    • The requested medication is being used to treat moderately to severely active ulcerative colitis in an adult.

    Initial Therapy — Crohn's Disease

    Coverage may be authorized for 12 months when ALL of the following are met:

    ALL of the following

    • The requested medication is being used to treat moderately to severely active Crohn's disease in an adult.

    Continuation Therapy — Ulcerative Colitis

    Continuation therapy may be authorized for 12 months when the member is using the requested medication for moderately to severely active ulcerative colitis and meets ANY of the following:

    ANY of the following

    • The member achieves or maintains remission.
    • Positive clinical response

      • The member achieves a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of ulcerative colitis.
      • Improvement from baseline in ANY of the following

        • Stool frequency
        • Rectal bleeding
        • Urgency of defecation

    Continuation Therapy — Crohn's Disease

    Continuation therapy may be authorized for 12 months when the member is using the requested medication for moderately to severely active Crohn's disease and meets ANY of the following:

    ANY of the following

    • The member achieves or maintains remission.
    • Positive clinical response

      • The member achieves a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of Crohn's disease.
      • Improvement from baseline in ANY of the following

        • Abdominal pain or tenderness
        • Diarrhea

    Other Coverage Requirements

    ALL of the following safety and concurrent-therapy requirements must be met:

    ALL of the following

    • The member has been evaluated for tuberculosis (TB) infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB.
    • The requested medication is not used concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    Under Tennessee Code Annotated Section 56-7-2352, BlueCross BlueShield of Tennessee covers off-label indications of FDA-approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in published peer-reviewed medical literature.

    Coverage may be authorized for treatment of moderately to severely active ulcerative colitis or Crohn's disease in adults, consistent with the FDA-approved indications for mirikizumab-mrkz (Omvoh).

    The requested medication cannot be used concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    All other indications are considered experimental/investigational and not medically necessary.

    Provider Actions and Requirements

    Prior Authorization

    12-Month Prior Authorization

    Prior authorization is required. Authorization may be granted for 12 months for treatment of moderately to severely active ulcerative colitis or Crohn's disease in adults.

    • Ulcerative colitis: 12-month authorization may be granted.
    • Crohn's disease: 12-month authorization may be granted.
    Note

    Gastroenterologist Involvement Required

    The medication must be prescribed by or in consultation with a gastroenterologist.

    Step Therapy

    Review Specialty Medication Step Therapy

    Background

    Mirikizumab-mrkz (Omvoh) is covered for adults with moderately to severely active ulcerative colitis or moderately to severely active Crohn's disease.

    Definitions

    Positive clinical response in ulcerative colitis
    DefinitionImprovement in signs and symptoms of moderately to severely active ulcerative colitis with low disease activity.
    Qualifying improvementImprovement from baseline in at least one measure: stool frequency, rectal bleeding, urgency of defecation, C-reactive protein (CRP), fecal calprotectin (FC), mucosal appearance on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound, or a disease activity score such as UCEIS or Mayo score.
    Authorization contextApplies to members using the requested medication for moderately to severely active ulcerative colitis; continuation authorization may be granted for 12 months.
    Positive clinical response in Crohn's disease
    DefinitionImprovement in signs and symptoms of moderately to severely active Crohn's disease with low disease activity.

    Initial Therapy Criteria

    Initial Therapy — Ulcerative Colitis

    Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

    Ulcerative colitis initial therapy: Member has moderately to severely active ulcerative colitis.Moderately to severely active

    The medication must be prescribed by or in consultation with a gastroenterologist and applicable safety requirements must be met.

    Initial Therapy — Crohn's Disease

    Authorization of 12 months may be granted for treatment of moderately to severely active Crohn's disease.

    Crohn's disease initial therapy: Member has moderately to severely active Crohn's disease.Moderately to severely active

    The medication must be prescribed by or in consultation with a gastroenterologist and applicable safety requirements must be met.

    Continuation Therapy Criteria

    Ulcerative Colitis Continuation

    Continuation authorization may be granted for 12 months when remission is achieved or maintained OR when a positive clinical response is demonstrated.

    Ulcerative colitis continuation outcomes

    • Member is using the requested medication for moderately to severely active ulcerative colitis and achieves or maintains remission.Remission

      Applies to all members, including new members.

    • Member is using the requested medication for moderately to severely active ulcerative colitis and achieves a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: stool frequency, rectal bleeding, urgency of defecation, C-reactive protein, fecal calprotectin, mucosal appearance on endoscopy, computed tomography enterography, magnetic resonance enterography, or intestinal ultrasound, or a disease activity score such as UCEIS or Mayo score.Improvement from baseline in at least one measure

    Step Therapy Requirements

    StepRequirementRelated policy
    1Some agents on this policy may require step therapy. Review the referenced document to determine whether mirikizumab-mrkz is subject to a step requirement.Step Therapy Requirements for Provider Administered Specialty Medications
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyMirikizumab-mrkz (Omvoh) Coverage Criteria
    Policy CodePolicy ID_CHS_6239
    Change TypeNo material change
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for coverage, and the medication must be prescribed by or in consultation with a gastroenterologist.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy Requirements
    C-reactive protein (CRP)
  1. Fecal calprotectin (FC)
  2. Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
  3. A disease activity scoring tool, such as the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) or Mayo score
  4. Body weight
  5. Abdominal mass
  6. Hematocrit
  7. Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
  8. A disease activity scoring tool, such as the Crohn's Disease Activity Index (CDAI) score
  9. Some agents on this policy may require step therapy. Providers should review the related specialty-medication step-therapy policy before requesting authorization.

    • Step Therapy Requirements for Provider Administered Specialty Medications: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf
    Step Therapy

    Potential Step Therapy Requirement

    Step therapy may be required for this medication. Refer to the related step-therapy policy for applicable requirements.

    • Step Therapy Requirements for Provider Administered Specialty Medications: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf
    Documentation Required

    Prior Authorization Documentation

    Submit documentation to support the prior authorization review. For continuation requests, provide chart notes or medical-record documentation demonstrating a positive clinical response to therapy or remission.

    • Documentation applies to ulcerative colitis and Crohn's disease.
    • Continuation requests require documentation of positive clinical response or remission.
    Denial Risk

    Unapproved Indications Not Covered

    Coverage is limited to the approved adult indications. All other indications are considered experimental or investigational and not medically necessary.

    • Moderately to severely active ulcerative colitis in adults.
    • Moderately to severely active Crohn's disease in adults.
    Denial Risk

    No Concurrent Biologic or Targeted Synthetic Therapy

    The requested medication cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Prior Authorization

    Tuberculosis Evaluation Required

    Confirm that the member has been evaluated for tuberculosis infection before initiating treatment with this biologic or targeted synthetic drug associated with an increased risk of tuberculosis.

    Qualifying improvement
    Improvement from baseline in at least one measure: abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound, or a disease activity score such as the Crohn's Disease Activity Index (CDAI).
    Authorization contextApplies to members using the requested medication for moderately to severely active Crohn's disease; continuation authorization may be granted for 12 months.
    Recognized standard reference compendia or published peer-reviewed medical literature
    DefinitionA standard reference compendium or published peer-reviewed medical literature recognized under Tennessee law as support for an off-label use of an FDA-approved drug.
    Covered off-label supportThe off-label use must be recognized in one of the statutorily recognized standard reference compendia or in published peer-reviewed medical literature.
    Applicable requirementCoverage of off-label indications of FDA-approved drugs is addressed under Tennessee Code Annotated Section 56-7-2352.

    Crohn's Disease Continuation

    Continuation authorization may be granted for 12 months when remission is achieved or maintained OR when a positive clinical response is demonstrated.

    Crohn's disease continuation outcomes

    • Member is using the requested medication for moderately to severely active Crohn's disease and achieves or maintains remission.Remission

      Applies to all members, including new members.

    • Member is using the requested medication for moderately to severely active Crohn's disease and achieves a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one of the following: abdominal pain or tenderness, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on endoscopy, computed tomography enterography, magnetic resonance enterography, or intestinal ultrasound, or a disease activity score such as CDAI.Improvement from baseline in at least one measure